CTIS2023-510362-26-00招募中1 期
Carvedilol vs. flecainida clinical trial in idiopathic ventricular arrhythmias. - CARFLECT IV
Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela0 个研究点目标入组 32 人开始时间: 2024年1月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients of legal age capable of consenting.
排除标准
- •Allergy or adverse effects after previously taking flecainide and/or carvedilol., Significant heart failure secondary to tachemocardiopathy., History of structural heart disease, including: ischemic heart disease, moderate or severe valvular disease, moderate or severe left ventricular hypertrophy, cardiac surgery, sarcoidosis, congenital heart disease (including Brugada syndrome, long QT syndrome, short QT syndrome, cardiomyopathy and other less common conditions)., Sinus dysfunction in patients who do not have pacemakers., Presence of accessory roads., Pregnancy and breastfeeding, since carvedilol is a drug that has been little studied in this context, which should be avoided if other alternatives are available., Having received electrophysiological procedures will only be an exclusion criterion if it was performed to ablate malignant ventricular arrhythmias., Previous intake of flecainide and/or beta-blockers at therapeutic doses with the same indication as in the study. Patients in whom low doses are started and referred without adequate titration will not be excluded., Little arrhythmic load in Holter-electrocardiogram (Holter-ECG) that does not explain the patient's symptoms. Patients with less than 1000 ventricular beats on the 24-h Holter-ECG will not be accepted., Liver failure., Chronic kidney disease with glomerular filtration rate <30 ml/m2/min., Second or third degree atrioventricular block., First degree atrioventricular block with PR >220 ms., Duration of the QRS complex >120 ms., Moderately or severely depressed left ventricular ejection fraction (<40%).
研究者
相似试验
进行中（未招募）
不适用
Comparison of the effect of carvedilol, ivabradine and their combination on exercise capacity in patients with heart failureMedDRA version: 14.1Level: PTClassification code 10007636Term: CardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10063083Term: Chronic left ventricular failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: LLTClassification code 10007561Term: Cardiac failure leftSystem Organ Class: 10007541 - Cardiac disordersheart failureEUCTR2011-002520-40-ITCASA DI CURA PRIVATA S.RAFFAELE - PISANA
已完成
不适用
Randomised controlled trial of carvedilol versus variceal band ligation in the primary prophylaxis of oesophageal variceal haemorrhageISRCTN26269039niversity of Edinburgh (UK)152
已完成
3 期
Randomized Controlled Trial of Carvedilol versus Rabeprazol Administration in the prevention of Esophageal Variceal Bleeding After Esophageal Variceal LigatioPatients after esophageal variceal ligation (EVL)JPRN-UMIN000003912Post-EVL Trial Office400
进行中（未招募）
不适用
Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT).EUCTR2012-000797-35-ESHospital Virgen de la Salud, Toledo (Spain).
进行中（未招募）
1 期
Quinidine or verapamil in short-coupled ventricular fibrillation.Short-coupled idiopathic ventricular fibrillation is a rare syndrome and subtype of idiopathic ventricular fibrillation that is characterized by ventricular fibrillation or polymorphic ventricular tachycardia (PVT) initiated by a short-coupled premature ventricular contraction (PVC).EUCTR2021-005688-36-NLAmsterdam UMC35